Business Wire - November 10, 2008
BALTIMORE--Contact phone number for Jeff Meshulam is 443-743-1107 (sted 443-543-5010).
The corrected release reads:
PROFECTUS BIOSCIENCES EXECUTES AN ASSIGNMENT AND LICENSE AGREEMENT WITH WYETH FOR VACCINES AGAINST HIV, HCV, HPV AND HSV
Leading R&D Company Will Continue Research for Both Therapeutic and Preventative Vaccines of Chronic Viral Diseases
Profectus BioSciences, Inc. (Profectus) announced today that it has executed an Assignment and License Agreement with Wyeth Pharmaceuticals that provides Profectus therapeutic/prophylactic vaccine programs for Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Human Papiloma Virus (HPV) and Herpes Simplex Virus (HSV). These programs combine the Wyeth proprietary technologies in the fields of DNA and vectored vaccines used alone and in a prime-boost strategy to prevent and treat infections.
The Agreement also provides Profectus with access to an extensive portfolio of intellectual property, research reagents, equipment, governmental funding and clinical trial products.
"Bringing the Wyeth portfolio into Profectus boosts our ability to develop innovative ways to treat patients inflicted with some of the most destructive viral diseases of our day," said Profectus President & CEO Shawn O'Brien. "The breadth and strength of the Wyeth portfolio, coupled with our expertise, will enable us to deliver a new class of vaccines into infected individuals with the first human trials projected to begin in 2009 for HIV followed closely by HCV. We are proud and honored to be the recipient of this portfolio and look forward to advancing this exciting class of vaccines to reduce morbidity and mortality."
The newly formed world-class team has over 150 years of combined experience in developing and delivering vaccines. One notable addition is John Eldridge, Ph.D., former VP of Wyeth Vaccines who joined Profectus as CSO, Vaccines.
About Profectus BioSciences Inc.
Profectus Biosciences is an R&D company dedicated to harnessing the immune system to prevent and treat chronic viral diseases and cancers through the delivery of proprietary prime/boost vaccines and small molecules. Profectus BioSciences Inc. commenced operations in early 2005. For more information please visit: www.profectusbiosciences.com.
Contacts
Profectus BioSciences | Jeff Meshulam, 443-743-1107 | meshulam@profectusbiosciences.com
or
Garfield Group | Kevin Jurrens, 215-867-8600 (x273) | Public Relations | kjurrens@garfieldgroup.com
081110
BW081115
Copyright © 2008 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .